Osivax Secures EUR 8 Million of Financing through a Series A Round to Develop Novel Universal Flu Vaccines and Expand oligoDOM® Technology Platform

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2Gk5Bxl
via IFTTT